NHS-Galleri Linked to Delays - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.

  • By

  • Andrea Surnit

  • June 4, 2026

  • 6 min

Share

Clinical Scorecard: NHS-Galleri Linked to Delays

At a Glance

CategoryDetail
Condition
Key MechanismsParticipation in the NHS-Galleri trial associated with increased diagnostic delays for certain cancers.
Target Population
Care Setting

Key Highlights

  • Modest increase in diagnostic delay rates observed in participating regions.
  • Average time to diagnostic resolution increased by about 2 days in participating regions.
  • 9,591 additional referrals experienced diagnostic delay during the first year of the trial.
  • Trial did not meet its primary endpoint of reducing combined stage III-IV cancer.

Guideline-Based Recommendations

Diagnosis

  • Monitor diagnostic delay rates in regions participating in trials.

Management

  • Consider downstream capacity needs when implementing MCED testing.

Monitoring & Follow-up

  • Evaluate the impact of trial participation on routine diagnostic services.

Risks

  • Be aware of potential harms such as false reassurance and diagnostic cascades.

Patient & Prescribing Data

Estimated nationwide rollout would cost about $19.2 billion annually for testing alone.

Clinical Best Practices

  • Assess socioeconomic factors in regions participating in trials.
  • Ensure adequate healthcare staffing in regions implementing new screening tests.

Related Resources & Content

Original Source(s)

NHS-Galleri Linked to Delays

  • by Andrea Surnit

  • June 4, 2026

Related Content

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

Does portal writing style contribute to disparities in clinician response?

Message length, punctuation, and clinician greetings were associated with intended clinician response.